Bristol-Myers Squibb

• E-mail

E-mail this article
To:
Invalid E-mail address
Add a personal message:(80 character limit) Your E-mail:
Invalid E-mail address

Sending your article
Your article has been sent.

Shares of Pfizer Inc. and Bristol-Myers Squibb Co. fell as regulators delayed for a second time a decision on the anticlotting drug Eliquis. Some analysts see Eliquis as better than two new clot-preventing pills that beat it to market, but the delay means a US launch probably won’t happen until next year. The FDA wants additional information on ‘‘data management and verification’’ from a huge international study.

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Sign up

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

Start here

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.

• E-mail

E-mail this article
To:
Invalid E-mail address
Add a personal message:(80 character limit) Your E-mail:
Invalid E-mail address

Sending your article
Your article has been sent.